Anthracycline Global Market Report 2024

The global anthracycline market has grown strongly in recent years. It will grow from $1.41 billion in 2023 to $1.52 billion in 2024 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to rising prevalence of cancer, growing demand for personalized cancer treatment, rising awareness of the benefits of anthracyclines, investment in anthracycline.

The global anthracycline market is expected to see strong growth in the next few years. It will grow to $1.97 billion in 2028 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to growing awareness about cancer treatment, investments in research and development for cancer treatments, growing demand for effective and convenient treatments for cancer, growing number of screening programs for cancer, government initiatives. Major trends in the forecast period include advancements in anthracycline formulations, combination therapies, cardioprotective strategies, developing biosimilars of anthracyclines.

The burgeoning prevalence of cancer is poised to act as a major catalyst for the future growth of the anthracycline market. Cancer, a group of disorders characterized by the unbridled proliferation of abnormal cells that can manifest in virtually any organ or tissue within the body, often transcending their typical boundaries and potentially spreading to other body parts or invading neighboring tissues. In this landscape, anthracyclines, a class of potent chemotherapy drugs, assume a crucial role in cancer treatment. They achieve this by impeding cell division through the disruption of DNA structure, effectively terminating its normal function. For instance, as of 2023, data from the American Cancer Society Inc., a US-based nonprofit health organization, projects a rise in new cancer cases with an estimated 1.9 million diagnoses in the United States. This marks an increase from the 1.8 million new cancer cases diagnosed in 2020. Furthermore, the anticipated figures for cancer-related deaths in 2023 stand at approximately 609,820, compared to the expected 606,520 in 2020. Consequently, the mounting incidence of cancer is the driving force behind the burgeoning anthracycline market.

The anthracycline market is primed for substantial growth in the foreseeable future, primarily attributed to the escalating adoption of personalized medicine. Personalized medicine, often referred to as precision medicine, represents a niche within medical treatment characterized by tailoring therapeutic approaches to the unique attributes of individual patients. This level of customization takes into account the genetic, molecular, and specific disease characteristics of patients, allowing for the precise integration of anthracycline chemotherapy drugs in combination with targeted therapies. The result is the delivery of more effective and less harmful treatment strategies.For instance, as of October 2022, reports from STAT, a US-based health-focused news entity, revealed that there are in excess of 75,000 genetic testing products and 300 personalized medicines in existence. Furthermore, data from the Personalized Medicine Coalition, a representative organization based in the United States, indicated that in 2022, the FDA approved personalized medicines for 34% of newly developed drugs. This trend has been consistent over the preceding eight years, with at least 25% of new drugs receiving approval as personalized medicines. Consequently, the escalating demand for personalized medicine stands as the driving force behind the expansion of the anthracycline market.

The growth of the anthracycline market faces hindrance during the forecast period due to the notable side effects associated with anthracycline use. Side effects serve as a substantial deterrent in the administration of anthracycline drugs, effectively diminishing the demand for these treatments. This limitation results in a reduction in available therapeutic options, often causing patient discomfort and non-adherence to treatment regimens. For instance, as of 2023, data from the National Library of Medicine, a US-based biomedical library, underscores the various side effects that anthracycline treatments can induce. These include symptoms such as chills, urticaria, pruritus, rashes, and heightened susceptibility to infections. In light of these side effects, the growth of the anthracycline market is notably impeded.

In the realm of anthracycline market dynamics, major companies are actively pursuing innovative drug developments, exemplified by products like Doxorubicin Liposome Injection, to solidify their market presence. For instance, in October 2021, Padagis LLC, an Israel-based pharmaceutical enterprise specializing in the production of generic prescription medications, made headlines with the FDA's (Food and Drug Administration) approval and launch of a generic rendition of Doxil, known as Doxorubicin Liposome Injection. This milestone marked the drug's introduction with an AB rating and came to fruition through a strategic collaboration with Ayana Pharma Ltd., an Israeli entity renowned for its development of liposomal drugs tailored for cancer therapeutics. Doxil Liposome Injection, classified as an anthracycline topoisomerase inhibitor, finds application in treating conditions such as ovarian cancer, Kaposi's sarcoma associated with AIDS (acquired immunodeficiency syndrome), and multiple myeloma. Its mode of action revolves around the inhibition or deceleration of cancer cell proliferation. Administration is achieved through intravenous injection, a process lasting 30 to 60 minutes or potentially longer. This example illustrates how innovative drug development and the production of generic alternatives are reshaping the anthracycline market.

In March 2021, Altaris Capital Partners LLC, a private equity firm headquartered in Denmark with a specialization in medical product investments, completed the acquisition of Padagis LLC from Perrigo Company PLC for a transaction valued at $1.55 billion. This strategic acquisition served as a means for Altaris Capital Partners LLC to broaden its portfolio in the realm of generic pharmaceutical products. Additionally, it facilitated access to the extensive expertise and resources held by Padagis LLC. Notably, Padagis LLC, headquartered in Israel, is a pharmaceutical company renowned for its production of generic anthracycline medications.

Major players in the anthracycline market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Bristol-Myers Squibb Company, Fresenius SE & Co. KGaA, Merck & Co. Inc., Gilead Sciences Inc., Zydus Lifesciences Limited, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Jazz Pharmaceuticals Inc., Gland Pharma Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Endo Pharmaceuticals Inc., Amneal Pharmaceuticals Inc., Zhejiang Hisun Pharmaceutical Co. Ltd., Accord Healthcare Limited, Athenex Inc., Miracalus Pharma Pvt. Ltd, Transo-Pharm Usa LLC, BluePoint Laboratories, Areva Pharmaceuticals Inc., GeneraMedix Inc., Salius Pharma Pvt. Ltd.

Asia-Pacific was the largest region in the anthracycline market in 2023. The regions covered in anthracycline report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the anthracycline market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The primary anthracycline drugs encompass daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, and valrubicin. Daunorubicin, for instance, serves as an anthracycline chemotherapy agent that operates by hindering the synthesis of both DNA and RNA. This inhibition is achieved through the intercalation of daunorubicin into the DNA helix, coupled with the inhibition of topoisomerase II. This dual mechanism results in cell cycle arrest and the induction of apoptosis, particularly in rapidly dividing cells. Anthracycline drugs are available in various formulations, including powders, capsules, solutions, injections, suspensions, and others. These formulations serve multiple therapeutic applications, addressing conditions such as acute lymphocytic leukemia, acute myelogenous leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, bladder cancer, breast cancer, and more. The diverse array of end users for these medications includes hospitals, home care settings, specialty clinics, and others.

This report provides anthracycline market statistics, including anthracycline industry global market size, regional shares, competitors with an anthracycline market share, detailed anthracycline market segments, market trends and opportunities and any further data you may need to thrive in the anthracycline industry. This anthracycline market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anthracycline market consists of sales of aclarubicin and pixantrone. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.